

Yifan Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1142760/publications.pdf>

Version: 2024-02-01

32
papers

1,955
citations

331670

21
h-index

454955

30
g-index

34
all docs

34
docs citations

34
times ranked

3114
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual-Loaded Liposomes Tagged with Hyaluronic Acid Have Synergistic Effects in Triple-Negative Breast Cancer. <i>Small</i> , 2022, 18, e2107690.	10.0	22
2	Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. <i>Nature Nanotechnology</i> , 2022, 17, 891-899.	31.5	74
3	Considerations for designing preclinical cancer immune nanomedicine studies. <i>Nature Nanotechnology</i> , 2021, 16, 6-15.	31.5	77
4	Self-Assembled pH-Sensitive Polymeric Nanoparticles for the Inflammation-Targeted Delivery of Cu/Zn-Superoxide Dismutase. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 18152-18164.	8.0	14
5	Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2007576.	21.0	42
6	Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease?. <i>Frontiers in Pharmacology</i> , 2021, 12, 695957.	3.5	12
7	High-Content Clonogenic Survival Screen to Identify Chemoradiation Sensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e27-e37.	0.8	5
8	Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 77.	3.7	46
9	Intelligent photothermal dendritic cells restart the cancer immunity cycle through enhanced immunogenic cell death. <i>Biomaterials</i> , 2021, 279, 121228.	11.4	41
10	Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 1712-1724.	7.0	76
11	Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. <i>Nature Biomedical Engineering</i> , 2020, 4, 69-83.	22.5	415
12	Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. <i>Nature Communications</i> , 2020, 11, 1508.	12.8	138
13	Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. <i>JAMA Network Open</i> , 2020, 3, e2028627.	5.9	22
14	Tumor Vasculatures: A New Target for Cancer Immunotherapy. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 613-623.	8.7	79
15	Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel. <i>Cancers</i> , 2019, 11, 1571.	3.7	34
16	Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. <i>Nature Communications</i> , 2019, 10, 4363.	12.8	61
17	Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery. <i>Advanced Science</i> , 2019, 6, 1802070.	11.2	82
18	Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2019, 17, 17-23.	1.7	24

#	ARTICLE	IF	CITATIONS
19	Clinical effect of postoperative chemoradiotherapy in resected advanced laryngeal squamous cell carcinoma. <i>Oncology Letters</i> , 2019, 17, 4717-4725.	1.8	0
20	The Reciprocity between Radiotherapy and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1709-1717.	7.0	95
21	Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 206-212.	1.7	6
22	Abstract 530: Phosphatidylserine-targeting antibody combined with chemoradiation enhances systemic anti-tumor immunity. , 2019, , .		0
23	RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 341-350.	7.0	31
24	Survival Patterns for Patients with Resected N2 Non-small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1968-1974.	1.1	36
25	Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 60-66.	2.0	38
26	Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5744-5756.	7.0	35
27	Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. <i>Frontiers in Pharmacology</i> , 2018, 9, 185.	3.5	277
28	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 763-769.	31.5	136
29	Chemoradiation Combined with Phosphatidylserine-Targeting Antibody Enhances Systemic Anti-tumor Immune Responses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S127.	0.8	0
30	Reduced Severe Toxicities in Elderly Esophageal Cancer Patients Treated with Intensity Modulated Radiation Therapy: A Population-Based Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E143-E144.	0.8	0
31	Hsp90 Inhibitor Ganetespib Sensitizes Non-small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. <i>Clinical Cancer Research</i> , 2016, 22, 5876-5886.	7.0	25
32	Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. <i>Anti-Cancer Drugs</i> , 2015, 26, 835-842.	1.4	5